Why the study?
Does sildenafil improve outcomes in infants with persistent pulmonary hypertension of the newborn when used as a supplement or alternative to inhaled nitric oxide?
Does sildenafil improve outcomes in infants with persistent pulmonary hypertension of the newborn when used as a supplement or alternative to inhaled nitric oxide?
This review explores the potential of sildenafil as an alternative or adjunct to inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn.
May support sildenafil as iNO adjunct or alternative in PPHN; leaves open efficacy confirmation in randomized trials.
Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening neonatal pathology resulting from poor hemodynamic and respiratory transition to extrauterine life. Inhaled nitric oxide (iNO) is a current, commonly used treatment of PPHN. However, some infants with PPHN do not respond to iNO therapy. Because of the significant morbidity and mortality associated with PPHN, it is useful to look at other possible therapies. This article explores the use of sildenafil in the treatment of PPHN, either as a supplement to iNO or as an alternative to iNO. Current research, including a case study, is reviewed. An emphasis is placed on the administration and efficacy of sildenafil in synergy with, and in lieu of, current iNO therapy in the treatment of PPHN.
No takes yet. Share an insight, caveat, or question.
Jana Spillers (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: